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Tortola et al. report that the E3 ubiquitin
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mediated cell fate. Hace1 deficiency
impairs TNF-driven NF-kB activation and
apoptosis and predisposes cells to
necroptosis. Consequently, hace1–/–
mice show enhanced colitis and colon
cancer, which can be reverted by
inactivation of pro-necroptotic kinase
RIP3 and TNFR1.
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The HECT domain E3 ligase HACE1 has been
identified as a tumor suppressor in multiple can-
cers. Here, we report that HACE1 is a central
gatekeeper of TNFR1-induced cell fate. Genetic
inactivation of HACE1 inhibits TNF-stimulated
NF-kB activation and TNFR1-NF-kB-dependent
pathogen clearance in vivo. Moreover, TNF-
induced apoptosis was impaired in hace1 mutant
cells and knockout mice in vivo. Mechanistically,
HACE1 is essential for the ubiquitylation of the
adaptor protein TRAF2 and formation of the
apoptotic caspase-8 effector complex. Intrigu-
ingly, loss of HACE1 does not impair TNFR1-
mediated necroptotic cell fate via RIP1 and RIP3
kinases. Loss of HACE1 predisposes animals to
colonic inflammation and carcinogenesis in vivo,
which is markedly alleviated by genetic inactiva-
tion of RIP3 kinase and TNFR1. Thus, HACE1
controls TNF-elicited cell fate decisions and
exerts tumor suppressor and anti-inflammatory
activities via a TNFR1-RIP3 kinase-necroptosis
pathway.Ce
This is an open access article under the CC BY-NINTRODUCTION
Posttranslational modifications play a key role in the regulation
of protein activity, localization, and stability, as well as in the con-
trol of protein-protein interactions. Among them, ubiquitylation
counts as one of the most prominent and best-characterized
modifications. Ubiquitin is a small protein that can be covalently
attached to lysine residues of other proteins through the interplay
of different ubiquitin-activating (E1) and -conjugating (E2) en-
zymes and ubiquitin ligases (E3) (Hershko and Ciechanover,
1998). The analysis of mice lacking various components of the
ubiquitylation machinery highlighted the importance of ubiquity-
lation in several cellular and physiological processes, spanning
from autophagy, transcription factor regulation, and DNA repair
to the control of cell cycle and cell death (Bergink and Jentsch,
2009; Bernassola et al., 2010; Hershko and Ciechanover, 1998;
Mukhopadhyay and Riezman, 2007), which in turn can affect
complex processes such as the immune response (Bhoj and
Chen, 2009; Corn and Vucic, 2014), the maintenance of tissue
homeostasis (Kumari et al., 2014), and tumorigenesis (Hoeller
and Dikic, 2009; Paolino et al., 2014).
Life or death cell fate decisions are critical for development,
against infectious diseases, or cancer formation. Apoptosis
was considered the sole form of programmed cell death dur-
ing development or disease (Elmore, 2007). However, besides
apoptosis, alternative programmed necrosis or necroptosisll Reports 15, 1481–1492, May 17, 2016 ª 2016 The Authors 1481
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
can be induced by death receptors (Vandenabeele et al., 2010).
Survival, apoptosis, and necroptosis can all be triggered by the
same cell-surface receptors. There has been intense interest in
how these fate decisions are made by identifying the gate-
keepers of apoptotic versus necroptotic cell fate and the
signaling cascades involved (Christofferson and Yuan, 2010).
One of the most paradigmatic signaling pathways that regulates
cellular fate is triggered by the tumor necrosis factor receptor 1
(TNFR1). TNFR1 engagement elicits cell survival pathways via
NF-kB induction (Beg and Baltimore, 1996; Van Antwerp et al.,
1996; Wang et al., 1998). When NF-kB activation is inhibited,
TNF stimulation triggers caspase-8-mediated apoptosis via
a defined death effector complex (Micheau and Tschopp,
2003; Wang et al., 1996). In specific conditions, blockade of
both NF-kB and apoptosis may result in programmed necrotic
cell death (Cho et al., 2009; He et al., 2009; Vanden Berghe
et al., 2014; Zhang et al., 2009). Necroptosis is mediated via
the RIP1/RIP3/MLKL kinase pathway and recently has been
implicated in normal development and in pathogenesis of dis-
eases, including ischemic injury, neurodegeneration, and intesti-
nal inflammation (Duprez et al., 2011; Kaiser et al., 2011; Kang
et al., 2013; Linkermann et al., 2012; Welz et al., 2011).
HECT domain and ankyrin repeat-containing E3 ligase 1
(HACE1) is an E3 ligase initially identified in the context of spo-
radic Wilms’ tumor (Anglesio et al., 2004). A number of reports
showed that HACE1 is downregulated in various types of tumors
(Anglesio et al., 2004; Hibi et al., 2008; K€uc¸€uk et al., 2013; Zhang
et al., 2007), and a previous study from our group highlighted the
important function of HACE1 as a tumor suppressor: mice lack-
ing HACE1 showed an increased propensity to develop sponta-
neous tumors as well as a reduced survival in different cancer
models (Zhang et al., 2007). In addition to this function, HACE1
has been implicated in Golgi membrane dynamics (Tang et al.,
2011), control of oxidative stress (Daugaard et al., 2013; Rotblat
et al., 2014), and heart failure following cardiac injury (Zhang
et al., 2014). However, the complexity of the molecular and
cellular processes potentially regulated by HACE1 is still largely
unexplored.
Here we report that HACE1 is a key regulator of TNFR1-
mediated cell fate. Genetic inactivation of hace1 impairs NF-
kB activation and apoptosis downstream of TNFR1, whereas
RIP3-regulated necroptotic cell fate is not affected. Importantly,
we found that hace1 mutant mice exhibit enhanced intestinal
inflammation and colon cancer following epithelial injury, which
can be rescued by simultaneous genetic inactivation of either
RIP3 or TNFR1.
RESULTS
HACE1 Controls TNFR1-Induced NF-kB Activation
To identify pathways relevant to HACE1 function, we scanned
the signaling pathways downstream of multiple ligand/recep-
tor pairs, using hace1 mutant (hace1–/–) mouse embryonic fi-
broblasts (MEFs). Intriguingly, hace1–/– MEFs stimulated with
TNF showed compromised phosphorylation and incomplete
degradation of the NF-kB inhibitor IkBa. As a consequence,
TNF-induced phosphorylation and activation of the NF-kB
subunit p65 was strongly reduced in hace1–/– MEFs (Fig-1482 Cell Reports 15, 1481–1492, May 17, 2016ure 1A). Impaired NF-kB activation was confirmed using
an electrophoretic mobility shift assay (EMSA) filter plate
assay (Figure 1B). Re-expression of wild-type (WT) HACE1 in
hace1–/– MEFs, but not that of the E3 ligase inactive HACE1
C876S mutant (Anglesio et al., 2004), restored TNF-induced
p65 NF-kB activation (Figure 1B; Figure S1A). Moreover,
TNF-induced NF-kB-dependent expression of interleukin-6
(IL-6) (Bollrath and Greten, 2009) also was markedly inhibited
in hace1-deficient MEFs (Figure 1C).
In addition to defective NF-kB induction, TNFR1-induced
JNK and consequent c-Jun phosphorylation were markedly
reduced in hace1–/– MEFs, a phenomenon that was accom-
panied by increased and prolonged ERK1/2 and p38-MAPK
phosphorylation (Figure 1A). TNFR1 and NF-kB are essential
for the in vivo clearance of the intracellular pathogen Listeria
monocytogenes (Pfeffer et al., 1993; Sha et al., 1995). Consid-
ering the observed in vitro defects in TNFR1/NF-kB activation,
we tested whether HACE1 also controls the response to
L. monocytogenes in vivo. Importantly, we observed impaired
clearance of L. monocytogenes (Figure 1D), accompanied by
enhanced lethality of the hace1–/– mice as compared to their
WT littermates (Figure 1E), a phenotype that is compatible
with and might be dependent on defective TNFR1/NF-kB acti-
vation. Thus, HACE1 E3 ligase activity is essential for TNF-
induced activation of both NF-kB and JNK downstream
signaling in vitro, and HACE1 controls in vivo immunity to
L. monocytogenes.
Impaired TNFR1-Induced Apoptosis in the Absence
of HACE1
When NF-kB activation is blocked, TNF stimulation results in
apoptotic cell death (Beg and Baltimore, 1996; Van Antwerp
et al., 1996; Wang et al., 1996). Given that TNF-mediated
NF-kB activation is impaired in hace1–/– cells, we reasoned
that loss of HACE1 might sensitize cells to TNFR1-induced
apoptosis. Surprisingly, TNF stimulation alone did not induce
significant cell death in hace1–/– cells (Figures 2A and 2B),
even when we monitored these cells for 72 hr (Figure S1B).
Moreover, whereas, as expected, control WT MEFs underwent
apoptosis in response to treatment with TNF and actinomycin-D
for 8 hr (ActD; used to block NF-kB anti-apoptotic transcriptional
activity; Lasek et al., 1996), hace1–/– MEFs remained resistant to
apoptotic death (Figures 2A and 2B) and cells remained viable,
albeit only partially, even at later time points (Figure S1C). Treat-
ment with ActD alone did not induce cell death in control nor
hace1–/– MEFs (Figure S1D).
Consistent with a critical role for HACE1 in mediating
TNF/ActD-induced apoptosis, activation of caspase-8 and its
downstream death effector caspase-3 as well as cleavage of
RIP1 kinase (RIP1) were markedly impaired in hace1–/– MEFs
(Figure 2C). We also failed to detect caspase-3 activation in
hace1–/– MEFs using a DEVDase activity assay (Figure S1E).
Similarly, apoptotic death and caspase-3 activation were absent
in hace1–/– MEFs challenged with TNF plus cycloheximide (CHX)
(Figure 2D; Figure S1F), an inhibitor of the NF-kB-mediated sur-
vival pathway (Tsuchida et al., 1995). Importantly, re-expression
of WT HACE1, but not E3 ligase-dead C876S HACE1, restored
TNF/ActD- as well as TNF/CHX-induced cell death in hace1–/–
Figure 1. HACE1 Is Essential for the TNFR1-
NF-kB Response
(A) Hace1+/+ and hace1–/– MEFs were stimulated
with murine TNF (10 ng/ml) to induce the activation
of TNFR1 downstream pathways. b-actin protein
levels are shown as controls. Results are repre-
sentative of three independent experiments.
(B) NF-kB activation of TNF (10 ng/ml) stimulated
(+) and untreated () hace1+/+ MEFs, hace1–/–
MEFs, hace1–/– MEFs re-expressing WT HACE1,
and hace1–/– MEFs re-expressing the E3 ligase-
dead C876S mutant. Triplicate filter plate assays
of nuclear extracts are shown as mean values ±
SD. HACE1 expression and re-expression were
confirmed by western blot.
(C) Time course of interleukin-6 (IL-6) induction in
hace1+/+andhace1–/–MEFsfollowingTNF(10ng/ml)
stimulation. IL-6 concentration was determined by
ELISA in triplicate (mean values ± SD).
(D) In vivo Listeria monocytogenes infections in
hace1+/+ and hace1–/– mice. Four days after
infection animals were sacrificed, spleen extracts
were plated, and bacterial loads in each spleen
were determined as colony-forming units (CFUs)/
spleen. Data for individual mice are shown.
(E) Kaplan-Meier survival curves of hace1+/+ and
hace1–/– mice after Listeria infections are shown
(p < 0.01).
See also Figure S1.MEFs (Figures 2E and 2F). SMAC mimetic drugs such as BV6
induce intrinsic apoptosis by blocking the inhibitor of apoptosis
(IAP) proteins downstream of TNFR1 (Vercammen et al., 1998;
Vucic et al., 2011). We therefore used this model as an addi-
tional trigger of TNF-induced apoptotic cell death. Baseline
cIAP1 and XIAP expression levels before and after TNF stimula-
tionwere comparable in control and hace1–/– MEFs (Figure S1G).
As expected, we observed TNF/BV6-induced cell death in con-
trol MEFs; by contrast, hace1–/– MEFs again were resistant to
apoptosis induced by TNF and BV6 (Figure S1H). These results
show that TNFR1-induced apoptosis depends on HACE1.
To test whether HACE1 also regulates TNFR1-mediated
apoptosis in vivo, we first challenged control and hace1–/– mice
with recombinant murine TNF. Hace1–/– mice were completely
resistant to TNF-induced death and systemic inflammation, as
determined by the liver injury markers ALT and AST (Figures 3A–
3C). To extend these data to additional in vivo models, we next
challenged mice with lipopolysaccharide (LPS)/D-Gal, which in-
duces liver damage and death in WT mice, but not in TNFR1
mutant mice (Pfeffer et al., 1993). Hace1 knockout mice were, to
a large extent albeit not completely, resistant to LPS/D-Gal-
induced liver damageand apoptotic death (Figures 3D–3F). TheseCell Rin vivo data indicate that hace1 deficiency
renders mice resistant to apoptotic liver
damage anddeath downstreamof TNFR1.
HACE1 Is aGatekeeper of Apoptotic
versus Necroptotic Cell Fate
In the condition where both NF-kB and
caspase activation are either geneticallyor pharmacologically blocked, TNF stimulation may result in a
non-apoptotic form of cell death termed necroptosis (Cho et al.,
2009; Christofferson and Yuan, 2010; Declercq et al., 2009; Gal-
luzzi and Kroemer, 2008). To determine whether loss of HACE1
also interferes with TNF-induced necroptosis, WT and hace1–/–
MEFs were pre-treated with the pan-caspase inhibitor Z-Val-
Ala-Asp-fluoromethyl ketone (Z-VAD) and then stimulated with
TNF/ActD to induce cell death. We observed that both WT and
hace1–/– MEFs are comparably sensitive to necroptosis triggered
by TNF/ActD/Z-VAD (Figure 4A). These findings also were
confirmed using TNF/CHX/Z-VAD as an alternative necroptotic
drug combination (Figure 4A). Of note, treatment with Z-VAD
alone or in combination with either ActD or TNF did not induce
cell death in control or hace1–/– MEFs (Figures S1D and S2A).
Two kinases, RIP1 and RIP3, mediate necroptotic cell fate
downstream of TNFR1 (Christofferson and Yuan, 2010; Declercq
et al., 2009). Pre-treatment with the specific RIP1 kinase inhibitor
necrostatin 1 (Nec-1) (Degterev et al., 2008) reverted necroptotic
cell death in both control and hace1–/– MEFs (Figure 4A). We next
generated hace1 ripk3 double-knockout (hace1–/– ripk3–/–) MEFs
to genetically determine the contribution of RIP3 on cell death in
hace1–/– MEFs. These double-mutant cells exhibited growtheports 15, 1481–1492, May 17, 2016 1483
Figure 2. Loss ofHace1 Confers Resistance
to TNF-Induced Apoptosis In Vitro
(A and B) Hace1–/– MEFs do not undergo
apoptosis. Cell viability (A) and representative im-
ages (B) are shown for hace1+/+ and hace1–/– MEFs
treated for 8 hr with either TNF alone (10 ng/ml) or
TNF + ActD (1 mg/ml). Cell viability was determined
in quadruplicate cultures (mean values ± SD). For
images, cells were stained with crystal violet.
Magnifications are 310.
(C) Levels of cleaved caspase-8 (cC8), cleaved
caspase-3 (cC3), total RIP1 kinase protein, and
cleaved RIP1 kinase (cRIP1) in lysates from
hace1+/+ and hace1–/– MEFs treated with TNF +
ActD for the indicated time points. GAPDH is
shown as a loading control.
(D) Cell viability of hace1+/+ and hace1–/– MEFs
untreated (control) or exposed for 8 hr to TNF alone
or TNF + cycloheximide (CHX; 10 mg/ml). Mean
survival (±SD) was determined in quadruplicate
cultures.
(E and F) Cell viability of hace1–/– MEFs re-ex-
pressing WT HACE1 and hace1–/– MEFs re-ex-
pressing the E3 ligase-dead C876S mutant left
untreated (control) or treated for 8 hr with TNF
alone and either TNF + ActD (E) or TNF + CHX (F).
Mean survival (±SD) was determined in quadru-
plicate cultures. Results are representative of more
than three independent experiments.
See also Figure S1.curves comparable to control MEFs (Figure S2B). Importantly,
whereas hace1–/– MEFs were sensitive to necroptosis, hace1–/–
ripk3–/– MEFs were resistant to necroptotic death (Figure 4B).
Thus, HACE1 is required for TNF-induced NF-kB activation
and apoptosis induction, but it is dispensable for the necroptotic
response following TNFR1 stimulation.
HACE1 Mediates TRAF2 Ubiquitylation within the
TNFR1-Receptor Complex
To identify molecular targets of HACE1 that could explain
impaired NF-kB activation and defective apoptosis downstream
of TNFR1, we established a HACE1-dependent in vitro ubiq-
uitylation assay using hemagglutinin (HA)-ubiquitin, the ubiqui-
tin-activating E1 enzyme, and multiple E2 enzymes. The most
efficient E2 for HACE1 E3 ligase activity was found to be
Ubc13 (Figure S3A). Using recombinant HACE1, Ubc13, the E1
enzyme, and HA-ubiquitin, we then performed in vitro ubiquityla-
tion assays on microchips spotted with >9,000 natively folded
human proteins. Intriguingly, our microchip array data revealed
multiple HACE1 ubiquitylation targets, many of which had been
annotated previously to the TNFR1/NF-kB-signaling pathway1484 Cell Reports 15, 1481–1492, May 17, 2016(Figures S3B and S3C). Using in vitro
ubiquitylation assays, we confirmed that
HACE1 directly ubiquitylates all targets
tested (not shown). Intriguingly, among
the substrates we found TRAF2.
Previous reports indicated that TRAF2
plays a pivotal role in driving NF-kB and
JNK activation and inhibiting necroptosisafter stimulation with TNF. This function is modulated by K63-
linked ubiquitylation of TRAF2 (Karl et al., 2014; Li et al., 2006,
2009; Petersen et al., 2015; Yeh et al., 1997). To identify the na-
ture of TRAF2 ubiquitylation mediated by HACE1, we performed
an in vitro ubiquitylation assay. We found that HACE1 directly
catalyzes K63-linked ubiquitylation of TRAF2 (Figure S4A).
Importantly, HACE1 is essential for this particular modification:
lack of HACE1 led to the abrogation of TNF-driven K63-linked
ubiquitylation of TRAF2 (Figure S4B). We failed to detect TNF-
induced K48-specific ubiquitylation of TRAF2 in control and
hace1–/– MEFs (Figure S4C) aswell as in in vitro ubiquitylation as-
says (not shown). Defective ubiquitylation was restored in
hace1–/– MEFs reconstituted with WT HACE1, but not in the E3
ligase-defective HACE1 C876S mutant (Figure S4D). Similar to
hace1–/– MEFs, RNAi-mediated downregulation of HACE1 in
WTMEFs impaired ubiquitylation of TRAF2 following TNF stimu-
lation (Figure S4E). These data indicate that HACE1 is a key regu-
lator of K63-linked ubiquitylation of TRAF2.
Activation of TNFR1 induces rapid formation of a TRAF2-
containing plasma membrane-bound signaling complex (com-
plex I) (Micheau and Tschopp, 2003). Within complex I, K63
Figure 3. Hace1–/– Mice Are Protected from
TNFR1-Induced Lethality In Vivo
(A–C) Hace1–/– mice are protected from liver
damage in response to a high-dose (450 mg/kg)
TNF challenge. (A) Kaplan-Meier survival curves
are shown for hace1+/+ and hace1–/– mice after
TNF injection (n = 6 mice per group, p < 0.05). (B)
Serum AST and ALT levels served as markers for
liver damage in littermate hace1+/+ and hace1–/–
mice following in vivo challenge with high-dose
TNF. Data from pooled sera (n = 4 mice per group)
are shown. (C) H&E staining of representative his-
tological liver sections 9 hr after the TNF challenge
is shown.
(D–F) Hace1–/– mice are protected from death in
response to LPS/D-Gal (LPS 10 mg/kg and D-Gal 1
g/kg mouse, i.p.). (D) Kaplan-Meier survival curves
of hace1+/+ and hace1–/– littermates injected
intravenously (i.v.) with a lethal dose of LPS/D-Gal
(n = 10 mice per group, p < 0.01). (E) H&E staining
and active caspase-3 immunodetection on liver
sections 7 hr after LPS/D-Gal injections are shown.
(F) Serum AST and ALT levels served as markers
for liver damage in littermate hace1+/+ and hace1–/–
mice following in vivo challenge with a lethal dose
of LPS + D-Gal. Data from pooled sera (n = 5 mice
per group) are shown.ubiquitylation of TRAF2 has been previously associated with the
ability to activate NF-kB and to induce JNK signaling (Habelhah
et al., 2004; Li et al., 2009; Liang et al., 2010; Xia and Chen,
2005). EndogenousHACE1associatedwith TRAF2, an interaction
that was markedly enhanced upon TNF stimulation (Figures S5A
and S5B). Moreover, endogenous HACE1 co-immunoprecipi-
tated with TNFR1 in WT MEFs, an interaction that appears to be
constitutive (Figures S5C and S5D). Cell surface expression of
TNFR1 in hace1–/– MEFs was comparable to that in control cells
(Figure S5E). Immunoprecipitation of complex I using FLAG-
tagged human TNF (Micheau and Tschopp, 2003) showed that
all the essential components of complex I, such as IKKa, IKKg,
TRAF2, as well as RIP1, were recruited to the activated TNFR1
in both control and hace1–/– MEFs (Figure 5A; Figure S5C).
RIP1 kinase appeared to be normally phosphorylated and
ubiquitylated within complex I (Figure 5A; Figures S5F and S5G).
Serial immunoprecipitation experiments, carried out to pull down
TRAF2 from the TNF-activated complex I (Lu et al., 2013), showed
amarked defect in K63 ubiquitylation of TRAF2 in hace1–/– versus
control MEFs (Figure 5B; Figure S5H). Thus, loss of HACE1 has no
apparent effect on the assembly of complex I; however, HACE1 is
essential for the ubiquitylation of complex I-associated TRAF2.
Impaired Assembly of the Caspase-8 Activation
Complex
Following initial formation of complex I, TNFR1 stimulation results
in the assembly of a secondary cytoplasmic complex, termedCell Rcomplex II (Micheau and Tschopp,
2003),whichdrivescaspase-8-dependent
apoptotic cell death (Declercq et al., 2009;
Kaiser et al., 2011; Oberst et al., 2011;
Welz et al., 2011). To investigate whetherthe observed resistance of hace1–/– MEFs to TNF-induced
apoptosis originates from defective complex II formation, we
analyzed the assembly of the apoptotic complex II following
TNF/ActD stimulation. In hace1–/– MEFs, the association of
TRAF2 with FADD (Figure 5C), as well as its TNF stimulation-
dependent associationwithRIP1 kinase (Figure 5D),was severely
impaired. Further in vitro assays using recombinant proteins
showed that TRAF2 and FADD interaction depends on ubiquity-
lation of TRAF2 (Figure S6A). Moreover, the recruitment of RIP1
kinase and caspase-8 to FADD also was severely affected (Fig-
ure 5E), demonstrating that loss of HACE1 expression results in
defective assembly of the caspase-8-activating complex.
Loss of HACE1 does not impair necroptosis downstream of
TNFR1 stimulation (Figure 4A). Necroptosis is mediated via the
formation of complex II containing, among other proteins,
FADD, caspase-8, and both RIP1 and RIP3 kinases. When cas-
pase-8 is inactivated, RIP1 and RIP3 kinases together induce
programmed necrosis (Cho et al., 2009; Christofferson and
Yuan, 2010; Declercq et al., 2009; Galluzzi and Kroemer, 2008;
Zhang et al., 2011). As reported previously (Wang et al., 2008),
Z-VAD inhibition of caspase-8 in TNF/ActD-treated WT MEFs
was associated with enhanced stability of the FADD/caspase-
8/RIP1 kinase complex (Figure 5E; Figure S6B). Intriguingly,
the association of RIP1 kinase and caspase-8 with FADD was
found to be virtually absent in hace1–/– MEFs undergoing TNF/
ActD/Z-VAD-triggered necroptosis (Figure 5E; Figure S6B). In
both control and hace1–/– MEFs, RIP3 kinase binds to RIP1eports 15, 1481–1492, May 17, 2016 1485
Figure 4. Hace1–/– Mutant Cells Undergo Necroptotis
(A) Hace1+/+ and hace1–/– MEFs were treated with TNF (10 ng/ml), Z-VAD (5 mg/ml), and Nec-1 (50 nM) plus either ActD (1 mg/ml) or CHX (10 mg/ml) using the
indicated combinations. Cell viability was determined in triplicates (mean values ± SD).
(B) Hace1+/+, hace1–/–, and hace1–/– ripk3–/– MEFs were treated with TNF (10 ng/ml), Z-VAD (5 mg/ml), Nec-1 (50 nM), and ActD (1 mg/ml). Cell viability was
determined in quadruplicates (mean values ± SD). Results are representative of at least three independent experiments.
See also Figure S2.kinase under necroptotic conditions (Figure 5F). This interaction
is mirrored by the phosphorylation of the necroptotic down-
stream mediator MLKL (Figure 5G) (Vanden Berghe et al.,
2014), indicating that induction of RIP1/RIP3-dependent necrop-
tosis is not affected by the absence of HACE1. Interestingly,
RIP1/RIP3 interactions can be detected, albeit at reduced levels,
in hace1–/– MEFs even under apoptotic conditions (Figure 5F).
However, we failed to detect any association between the
RIP1/RIP3 kinases and caspase-8 under necroptotic conditions
in hace1–/– MEFs treated with either TNF/ActD/Z-VAD or with
TNF/BV6/Z-VAD (Figures S6B and S6C) (He et al., 2009). Impor-
tantly, we still observed RIP1 phosphorylation, a marker of RIP1
kinase activity and necroptotic pre-disposition (Declercq et al.,
2009), in both control and hace1–/– MEFs treated with TNF/
ActD/Z-VAD (Figure 5E; Figure S6B) or TNF/BV6/Z-VAD (Fig-
ure S6C). Thus, loss of HACE1 expression impairs the assembly
of the canonical complex II without any apparent effect on the
formation and activity of the necrosome formed by RIP1 and
RIP3 kinases and phosphorylation of MLKL.
Hace1-Deficient Mice Are Hyper-susceptible
to DSS-Induced Colitis
Our data so far showed that loss of HACE1 protects cells
from TNF-induced apoptosis in vitro while leaving TNF-mediated
RIP1/RIP3 kinase-dependent necroptosis intact. Since TNFR1,
NF-kB, and RIP3 kinase recently have been implicated in intesti-
nal homeostasis (G€unther et al., 2011; Pasparakis, 2009; Welz
et al., 2011), we tested whether HACE1 might play a role in gut
inflammation. Naive hace1–/– mice showed normal body weight
(Figure S7A), and morphological and flow cytometric analyses
of the intestine of naive hace1–/– mice did not reveal any overt
alteration compared to WT littermates (Figures S7B and S7C).1486 Cell Reports 15, 1481–1492, May 17, 2016However, when we challenged mice with dextran sodium sulfate
(DSS), a chemical irritant that disrupts the intestinal epithelial
barrier and induces colitis (De Robertis et al., 2011), we observed
markedly increased intestinal inflammation in hace1–/– versus
control hace1+/+ mice. Hace1–/– mice suffered a more pro-
nounced weight loss than WT mice when treated with DSS (Fig-
ure 6A), and histopathological analysis revealed markedly more
severe inflammation, tissue destruction, and epithelial cell death
in hace1–/– mice compared to WT littermate controls (Figure 6B;
Figure S7D). In addition, hace1–/– mice showedmore severe diar-
rhea and increased intestinal bleeding (hemoccult test) compared
toWT littermates (Figures 6C and6D). Flowcytometric analysis of
the immune system in the lamina propria revealed markedly
increased infiltration of CD11b+Gr-1+ Ly6G– inflammatorymono-
cytes in the intestines of hace1-deficientmice after treatmentwith
DSS (Figure 6E), confirming the increased severity of intestinal
inflammation in hace1–/– compared to control WT mice.
Both NF-kB and TNFR1 pathways play fundamental roles in
immunity. NF-kB acts downstream of surface receptors recog-
nizing pro-inflammatory cytokines, including TNF itself, as well
as pathogen-associated pattern receptors, which in turn leads
to the expression of further inflammatory mediators (Bonizzi
and Karin, 2004). On the other hand, NF-kB expression in
epithelia such as the intestine plays a fundamental role in
ensuring epithelial cell survival and in maintaining the structural
integrity of mucosal surfaces (Pasparakis, 2009). Hace1 mRNA
is expressed at comparable levels in a variety of immune cells
as well as in intestinal epithelial cells (Figure S7F). To discern in
which cells HACE1 is acting to prevent severe colitis, we gener-
ated bone marrow chimeric mice lacking HACE1 exclusively in
the immune systemby transferring hace1-deficient bonemarrow
cells in lethally irradiated hace1-sufficient host mice. As T cells in
Figure 5. Complex I and Complex II For-
mation
(A) Hace1+/+ and hace1–/– MEFs were stimu-
lated with FLAG-tagged human TNF (FLAG-hTNF,
50 mg/ml) for the indicated time points followed by
an anti-FLAG immunoprecipitation to detect pro-
teins associated with the activated TNFR1 (com-
plex I). FLAG-immunoprecipitates (IPs) and input
lysates were probed with antibodies to IKKa, RIP1
kinase, TRAF2, and TNFR1. RIP1 kinase ubiq-
uitylation as well as phosphorylation (p-RIP1) are
indicated.
(B) Serial immunoprecipitation of TRAF2 from the
activated TNFR1 complex. Western blots were
probed to detect K63-ubiquitylated TRAF2.
(C) Interactions of TRAF2 with FADD were deter-
mined in anti-TRAF2 IPs from TNF- (10 ng/ml)
stimulated (+) and untreated () hace1+/+ and
hace1–/– MEFs.
(D) RIP1/TRAF2 interactions in hace1+/+ and
hace1–/– MEFs were determined by western
blot on TRAF2 IPs from TNF-stimulated (+) and
untreated () MEFs.
(E) Hace1+/+ and hace1–/– MEFs were treated with
TNF (10 ng/ml), ActD (1 mg/ml), Z-VAD (5 mg/ml),
and Nec-1 (50 nM) for 90 min followed by immu-
noprecipitation of FADD to detect FADD-RIP1
kinase and FADD-caspase-8 interactions. Ly-
sates were assayed for protein expression of
RIP1, caspase-8 (C8), and FADD. Phosphorylated
RIP1 kinase (p-RIP1) is indicated.
(F) Hace1+/+ and hace1–/– MEFs were stimu-
lated (+) or untreated () with TNF (10 ng/ml), ActD
(1 mg/ml), and Z-VAD (5 mg/ml). Lysates were
immunoprecipitated with anti-RIP1 antibodies to
detect RIP1/RIP3 kinase interactions.
(G) Hace1+/+ and hace1–/– MEFs were left un-
treated () or stimulated (+) with TNF (10 ng/ml),
ActD (1 mg/ml), and Z-VAD (5 mg/ml). Western blots
show levels of total and phosphorylated MLKL
(p-MLKL) at the indicated time points.
See also Figures S3–S6.the intestine are largely radioresistant, we used lymphopenic
rag2–/– mice as hosts (KO/rag2–/–) to prevent host-derived
WT T cells to persist in the intestine, thus affecting the validity
of the system. As a control group, we reconstituted irradiated
rag2–/– mice with WT bone marrow (WT/rag2–/–). Treatment
of these chimeric mice with DSS revealed that the absence or
presence of HACE1 in the immune system had no apparent
effect on the development of colitis: both groups showed com-
parable weight loss (Figure S7G) and similar recruitment of in-
flammatory cells to the intestinal lamina propria (Figure S7H).
These results indicate that the loss of HACE1 in radiosensitive
immune cells is not responsible for the increased susceptibility
of hace1–/– mice to colitis.
Importantly, genetic inactivation of RIP3 kinase in hace1–/–
ripk3–/– double-knockout mice and inactivation of TNFR1 in
hace1–/– tnfr1–/– double-knockout mice completely rescued all
parameters of the severe inflammatory phenotype in hace1–/–
mice to levels observed in WT littermates, including weightloss, tissue damage, death of epithelial cells, recruitment of
inflammatory cells, as well as diarrhea and intestinal bleeding
(Figures 6A–6E; Figure S7D). Also, the expression of several
pro-inflammatory mediators was upregulated in the colon of
hace1–/– mice; in hace1–/– tnfr1–/– and hace1–/– ripk3–/– mice
the levels of these pro-inflammatory factors were again restored
to levels detected in WT controls (Figure S7E). The increased
death of intestinal epithelial cells in DSS-treated hace1–/– mice
is probably the consequence of exaggerated immune activation
and inflammation resulting from the preferential induction of
TNF-driven necroptosis instead of apoptosis in the absence of
HACE1 (Pasparakis and Vandenabeele, 2015). Of note, while
others reported increased severity of colitis in ripk3–/– (Moriwaki
et al., 2014) and, to a lesser extent, in tnfr1–/– mice (Stillie and
Stadnyk, 2009; Wang et al., 2012), in our hands single-knockout
mice showed no change in weight loss compared to WT litter-
mates (Figure 6F). The difference in ripk3–/– mice might be due
to the time point of analysis: Moriwaki et al. (2014) reported aCell Reports 15, 1481–1492, May 17, 2016 1487
Figure 6. Deletion of RIP3 Kinase or TNFR1
Alleviates the Severe Colitis inHace1–/–Mice
(A) Percentage body weight changes during 7-day
administration of DSS (2.5%) in WT, hace1–/–,
hace1–/– ripk3–/–, and hace1–/– tnfr1–/– mice are
shown.
(B) Representative colonic histopathology (H&E
staining) from WT, hace1–/–, hace1–/– ripk3–/–, and
hace1–/– tnfr1–/– mice after 7 days of treatment with
DSS. Lower histology panels depict magnifica-
tions of the selected areas.
(C and D) Diarrhea and blood scores of WT,
hace1–/–, hace1–/– ripk3–/–, and hace1–/– tnfr1–/–
mice treated with DSS for the indicated time
periods. Data are shown as mean values ± SD (n =
5 mice per group). The p values are relative to
DSS-treated hace1–/– versus all other genotypes
(WT, hace1–/– ripk3–/–, and hace1–/– tnfr1–/–).
(E) Myeloid cell recruitment to the colonic lamina
propria of DSS-treated mice. Neutrophils were
defined as CD11b+ Gr-1+ Ly6G+, inflammatory
monocytes as CD11b+ Gr-1+ Ly6G–, and dendritic
cells (DCs) as CD11b+/– CD11clo/+ Gr-1–. All data in
(B)–(E) are from mice at day 7 after DSS adminis-
tration. Values show average ± SEM. Results are
representative of more than three independent
experiments.
(F) Body weight changes during 7-day adminis-
tration of DSS (2.5%) in WT, ripk3–/–, and tnfr1–/–
mice (n = 5 per group).
See also Figure S7.defect of ripk3–/– animals in the recovery from DSS, while we
focused on the earlier phase of tissue destruction during which
enhanced necroptosis is known to be detrimental (G€unther
et al., 2011). Together, our data show that the increased suscep-
tibility of hace1-deficient mice to DSS-induced colitis depends
on deregulated TNFR1 signaling and RIP3 kinase.
Hace1 Controls Colon Cancer via TNFR1 and RIP3
Kinase
We initially identified HACE1 as a tumor suppressor gene down-
regulated in multiple cancers (Anglesio et al., 2004; Zhang et al.,
2007). Since we observed increased intestinal inflammation, we
next explored whether hace1–/– mice are prone to develop colon
cancer upon challenge with DSS and the genotoxic drug azoxy-
methane (AOM) (Tanaka et al., 2003). Since hace1–/– mice are
particularly sensitive to DSS, we reduced the DSS treatment1488 Cell Reports 15, 1481–1492, May 17, 2016regimen to a level not sufficient to induce
colon cancer in WT mice (De Robertis
et al., 2011; Tanaka, 2012). As expected
using this low DSS dose, we failed to
detect any tumors in control HACE1-
expressing mice (Figure 7A). However, in
hace1–/– mice, we observed a markedly
increased incidence of colon cancer as
determined by colonoscopy or histopath-
ological examination (Figures 7A and 7B).
Colonic tumors in hace1–/– mice show
features consistent with adenomatouspolyps as well as nuclear atypia, multiple mitotic figures, areas
of carcinoma in situ, and focal invasion (Figure 7B). Most impor-
tantly, hace1–/– ripk3–/– as well as hace1–/– tnfr1–/– double-
knockout mice were similar to WT mice and did not show
AOM/DSS-induced colonic tumors (Figures 7A and 7B), indi-
cating that simultaneous genetic inactivation of TNFR1 and
RIP3 kinase considerably reduced colon cancer formation sec-
ondary to hace1 deficiency. In conclusion, hace1 deficiency pre-
disposes to colonic inflammation and carcinogenesis, which is
markedly alleviated by genetic inactivation of TNFR1 and RIP3
kinase.
DISCUSSION
Our results highlight HACE1 as a gatekeeper for TNFR1-
mediated cell fates. Loss of HACE1 impairs TNFR1-mediated
Figure 7. Genetic Inactivation of ripk3 or
tnfr1 Reverts the Sensitivity of hace1–/–
Mice to DSS + AOM-Induced Colon Cancer
(A) Representative colonoscopies and incidence
of colon cancer of hace1+/+, hace1–/–, hace1–/–
ripk3–/–, and hace1–/– tnfr1–/– mice (n = 5 mice per
cohort) after 7 weeks of treatment with AOM +
DSS. Arrow indicates tumor.
(B) Colonic histopathology (H&E stainings) on tis-
sues harvested 14 weeks after AOM-DSS chal-
lenge. Note the large adenoma in hace1–/– mice,
whereas no aberrant hyperplasias or adenomas
were observed in hace1+/+, hace1–/– ripk3–/–, and
hace1–/– tnfr1–/– mice. Magnifications are 310;
inset magnification are 340. Experiments were
repeated two more times with similar cohort sizes
and we always observed analogous results.activation of NF-kB signaling and apoptosis in vitro and in vivo,
but it does not inhibit TNFR1-dependent RIP1/RIP3-induced
necroptosis. Moreover, our data show that enhanced inflamma-
tion and colon cancer in hace1 mutant mice can be reverted by
genetic inactivation of RIP3 kinase and TNFR1.
We propose the following scenario for HACE1-regulated NF-
kB activation downstream of TNFR1. Loss of HACE1 does not
impair formation of complex I at TNFR1; however, NF-kB and
JNK activation are markedly impaired in hace1–/– MEFs, a func-
tion dependent on its E3 ligase activity. Our results indicate that
HACE1 expression is essential for K63 ubiquitylation of TRAF2
within complex I upon TNFR1 stimulation, which previously has
been associated with the ability to activate the canonical NF-
kB pathway and to induce JNK signaling (Habelhah et al.,
2004; Liang et al., 2010; Xia and Chen, 2005). Although NF-kB
signaling is impaired, hace1–/– MEFs do not undergo apoptosis
in response to TNFR1 stimulation, which can be biochemically
explained by the fact that hace1–/– cells fail to form pro-apoptotic
complex II. Moreover, our results show that TRAF2 ubiquitylation
is required for TRAF2 to associate with the key death molecule
FADD, which in turn nucleates the caspase-8 apoptosis effector
complex. However, besides TRAF2, we found multiple addi-
tional HACE1 ubiquitylation targets that previously have beenCell Rlinked to cell death and signaling path-
ways downstream of TNFR1, suggesting
that HACE1 could regulate TNFR1-regu-
lated cell fate at various interception
points.
Our in vitro and in vivo data indicate that
necroptosis in hace1mutant cells is medi-
ated via the RIP1/RIP3/MLKL pathway.
Since we failed to detect formation of an
intact necrosome, such death signals
might progress independently of the ca-
nonical molecular necroptotic complex.
Necroptosis in the context of hace1 defi-
ciency appears to occur without direct
caspase-8 interaction with RIP1/RIP3 ki-
nases, raising the possibility that alterna-
tive RIP1/RIP3 kinase complexes mightexist when HACE1 is inactivated. Of note, in our experimental
system, induction of necroptosis in hace1 knockout MEFs still
requires caspase inhibition via Z-VAD. Whether regulation of
cFLIP (Oberst et al., 2011) could explain this remaining caspase
dependency requires further exploration. Moreover, a feedback
inhibition loop via RIP3 kinase activity has been reported recently
in the control of caspase-8-mediated apoptosis (Newton et al.,
2014), suggesting complex interplays between the apoptotic
and necroptotic death effector machineries.
We initially identified HACE1 as a candidate tumor suppressor
gene in a child with Wilms’ tumor (Anglesio et al., 2004; Zhang
et al., 2007). In accord with its putative tumor suppressor func-
tion, we found HACE1 to be downregulated in multiple cancers
(Hibi et al., 2008; Sakata et al., 2009). That HACE1 can indeed
suppress cancer was shown in hace1 knockout mice that
develop tumors of multiple tissues (Zhang et al., 2007). Since
the TNFR1 and RIP1/RIP3 kinase pathway has been reported
to induce oxidative stress and possibly alter cellular metabolism
(Christofferson and Yuan, 2010; Declercq et al., 2009; Galluzzi
and Kroemer, 2008), our results suggest that this activation
pathway downstream of TNFR1 might not only trigger necropto-
sis but also could be involved in oncogenesis. Moreover, RIP1/
RIP3 kinases downstream of TNFR1 have been implicated in aeports 15, 1481–1492, May 17, 2016 1489
pro-inflammatory cascade in the intestine unleashed by SMAC
mimetics or caspase-8 deficiency (Kang et al., 2013; Vince
et al., 2012), driven by the release of necroptosis-mediated dam-
age-associated molecular pattern molecules (DAMPs) (Duprez
et al., 2011; Kaczmarek et al., 2013). Hace1mutant mice indeed
develop increased intestinal inflammation following epithelial
injury and increased incidence of colon cancer. Importantly, ge-
netic deletion of either RIP3 kinase or TNFR1 not only reversed
the enhanced inflammation but also strongly reduced the devel-
opment of colon cancer in hace1 single-mutant mice. These data
demonstrate that deregulation of the TNFR1-mediated RIP3 ki-
nase signaling is a key driving principle of inflammation and sub-
sequent colon cancer development controlled by HACE1.
EXPERIMENTAL PROCEDURES
Mice and Study Approval
The mice, hace1+/+, hace1–/–, hace1–/– tnfr1–/–, and hace1–/– ripk3–/– on a
C57BL/6 background, were bred and maintained under specific pathogen-
free conditions at the Institute of Molecular Biotechnology of the Austrian
Academy of Sciences (IMBA) animal facility. For experiments, age- and sex-
matched mice (8–12 weeks of age) were used. All animal experiments were
approved by Austrian authorities, and mice were kept following the guidelines
of Austrian animal laboratory law.
Cell Lines and Western Blots
MEFs derived from hace1+/+ and hace1–/– mice were prepared as described
previously (Zhang et al., 2007). MEFs were seeded at 2 3 106 cells per
60-cm2 Petri dish and cultured in DMEM supplemented with 5% fetal calf
serum (FCS) and 1% Pen-Strep (Sigma) in a 5% CO2 incubator. The next
day, cells were treated with 10 ng/ml mouse TNF (3014, Immunotools),
1 mg/ml ActD-Mannitol (A-5156, Sigma), 5 mg/ml Z-VAD (Bachem), and
50 nM Nec-1 (N-9037, Sigma). In addition, cells were treated with 10 ng/ml
mouse TNF (3014, Immunotools) and 10 mg/ml CHX (C1988, Sigma). Following
the treatments, the cells were lysed in 1 ml ice-cold NP-40 buffer (10 mM Tris
[pH 8.0], 150 mM NaCl, and 1% Nonidet P-40) supplemented with protease
and phosphatase inhibitor tablets (11873580001 and 04906837001, Roche).
The lysates were then centrifuged at 14,000 rpm for 10 min at 4C. Immuno-
precipitations were performed according to the manufacturer’s protocol.
In Vivo Lethality Experiments
For high-dose lethal TNF challenge, animals were injected via the tail vein with
450 mg/kg of purified endotoxin-free TNF (Immunotools) in 200 ml PBS (pH 6.8).
For induction of hyper-acute shock, TNF was used at a dose of 5 mg/kg. LPS
(L2880, Sigma) was administrated intraperitoneally (i.p.) at a concentration of
10 mg/kg. D-Gal (G0500, Sigma) was given to mice together with LPS at a
concentration of 1 g/kg. Liver enzymes were assayed using the Cobas C111
system (Roche). For histology, livers were embedded in paraffin, sectioned,
and stained with H&E.
Listeria Infections
Listeria monocytogenes (strain LO28) was prepared for infection as described
previously (Stockinger et al., 2009). The bacterial suspension (500 ml) was in-
jected into the peritoneum of 8- to 10-week-old male hace1+/+ and hace1–/–
littermatemice. Survival of infectedmicewasmonitored for 10 days. For deter-
mination of the bacterial load, mice were euthanized 96 hr after infection
and spleens were homogenized in PBS. Serial dilutions of homogenates
were plated on Oxford agar plates and colonies were counted after growth
at 37C for 24 hr.
Statistics
If not otherwise stated, all data are expressed as themeans ± SD. Significance
was assessed by Student’s two-sided t test unless otherwise stated in the
figure legends. For multiple comparisons, we used a two-way ANOVA test1490 Cell Reports 15, 1481–1492, May 17, 2016with a Bonferroni post-test. Differences with p values <0.05 were considered
as significant (*p < 0.05, **p < 0.01, and ***p < 0.001).
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